The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel--a drug used to treat rheumatoid arthritis and other inflammatory conditions--allowing Amgen to extend its monopoly over the biologic drug.
View Press Release: https://www.ftc.gov/news-events/news/press-releases/2026/08/ftc-files-amicus-brief-protect-competition-biologic-drug-markets